The Role of High-Efficacy Therapies in Multiple Sclerosis Treatment: Patricia K. Coyle, MD

At the 2025 ACTRIMS Forum, the director of the MS Comprehensive Care Center at Stony Brook Medicine discussed the evolution of high-efficacy treatments for MS. [WATCH TIME: 4 minutes]:

Source: Neurology Read More

Previous PostKetogenic Diet Shows Potential for Modulating Immune Response in Multiple Sclerosis
Next PostPilavapadin Heads for Phase 3 Trial Following Positive PROGRESS Study of Neuropathic Pain

The Role of High-Efficacy Therapies in Multiple Sclerosis Treatment: Patricia K. Coyle, MD

Previous PostKetogenic Diet Shows Potential for Modulating Immune Response in Multiple Sclerosis

Next PostPilavapadin Heads for Phase 3 Trial Following Positive PROGRESS Study of Neuropathic Pain

Related Posts

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

<![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

<![CDATA[GLP-1 Receptor Agonists Show Translational Potential in Alzheimer Disease Despite Mixed Study Results]]>

Categories